Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jun;5(3):343-6.
doi: 10.21037/tlcr.2016.03.05.

Alectinib-a new chapter in the management of ALK-positive lung cancer

Justin F Gainor  1
Affiliations
Comment

Alectinib-a new chapter in the management of ALK-positive lung cancer

Justin F Gainor. Transl Lung Cancer Res. 2016 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: JF Gainor has served as a compensated consultant for Novartis, Merck, Clovis, Genentech-Roche, Bristol-Myers Squibb, Boehringer Ingelheim, Jounce Therapeutics, and Kyowa Hakko Kirin.

Comment on

References

    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. 10.1038/nature05945 - DOI - PubMed
    1. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31:1105-11. 10.1200/JCO.2012.44.5353 - DOI - PMC - PubMed
    1. Antoniu SA. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703. Expert Opin Ther Targets 2011;15:351-3. 10.1517/14728222.2011.550880 - DOI - PubMed
    1. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77. 10.1056/NEJMoa1408440 - DOI - PubMed
    1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. 10.1056/NEJMoa1214886 - DOI - PubMed

LinkOut - more resources